AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18070967 — intervention group
Group type: COMPARATOR
Intervention: LPV-RTV
Number of subjects: 342
Study 17126779 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (5 mL/kg)
Number of subjects: 20
Study 17126779 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (25 mL/kg)
Number of subjects: 20
Study 17126779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fluids
Number of subjects: 20
Study 17126779 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 20
Study 17126779 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 20
Study 14566178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low iodine concentration (300 mg/mL) at slow flow rate (2.5 mL/s)
Number of subjects: 60
Study 14566178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast concentration (300 mg/mL) at high flow rate (3.5 mL/s)
Number of subjects: 60
Study 14566178 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast concentration (400 mg/mL) at high flow rate (3.5 mL/s)
Number of subjects: 60
Study 14566178 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximately 1 g iodine/s
Number of subjects: 60
Study 10926127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette describing AIDS as lethal
Number of subjects: 136
Study 10926127 — intervention group
Group type: COMPARATOR
Intervention: Vignette describing AIDS as chronic
Number of subjects: 136
Study 10926127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vignettes (lethal vs chronic)
Number of subjects: 136
Study 10926127 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial variables
Number of subjects: 136
Study 8900980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovolemic condition (induced by 30 mg furosemide)
Number of subjects: 8
Study 8900980 — intervention group
Group type: COMPARATOR
Intervention: Normovolemic condition
Number of subjects: 8
Study 8900980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovolemic condition
Number of subjects: 8
Study 2049253 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (Prostaglandin E1) infused at doses ranging from 0.01 to 1.3 micrograms kg‐1 min‐1
Number of subjects: 10
Study 2049253 — intervention group
Group type: COMPARATOR
Intervention: Control saline solution (isotonic)
Number of subjects: 10
Study 6404193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 14
Study 6404193 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium Cromoglycate (DSCG)
Number of subjects: 14
Study 30412032 — intervention group
Group type: COMPARATOR
Intervention: HYP-PLA (placebo drink in hypoxia)
Number of subjects: 12
Study 30412032 — intervention group
Group type: COMPARATOR
Intervention: NORM-PLA (placebo drink in normoxia)
Number of subjects: 12
Study 30412032 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP-CHO (carbohydrate solution in hypoxia)
Number of subjects: 12
Study 30174193 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass surgery with minimal gastric resection
Number of subjects: 21
Study 30174193 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 21
Study 28095936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioprotective diet
Number of subjects: 40
Study 28095936 — intervention group
Group type: COMPARATOR
Intervention: Conventional UK diet
Number of subjects: 40
Study 26813138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of the Intersphincteric Fistula Tract Plus Bioprosthetic Anal Fistula Plug (LIFT‐plug)
Number of subjects: 239
Study 26813138 — intervention group
Group type: COMPARATOR
Intervention: LIFT (control)
Number of subjects: 239
Study 24643485 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention program (physical activity and nutrition)
Number of subjects: 27
Study 24643485 — intervention group
Group type: EXPERIMENTAL
Intervention: Plus intervention program (physical activity and nutrition)
Number of subjects: 27
Study 24643485 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 21242192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 10837
Study 21242192 — intervention group
Group type: COMPARATOR
Intervention: No vitamin E
Number of subjects: 10837
Study 18495372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech external beam therapy (EBT)
Number of subjects: 9
Study 18495372 — intervention group
Group type: COMPARATOR
Intervention: High-tech brachytherapy (BT)
Number of subjects: 9
Study 16541932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (six or more face-to-face contacts)
Number of subjects: 160
Study 16541932 — intervention group
Group type: COMPARATOR
Intervention: Non-intensive rehabilitation (three or less face-to-face contacts)
Number of subjects: 160
Study 12656706 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help program with e-mail support + weekly individual telephone calls
Number of subjects: 44
Study 12656706 — intervention group
Group type: COMPARATOR
Intervention: Web-based self-help program with e-mail support (Internet-only group)
Number of subjects: 44
Study 11023140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (goal HbA(1c) 7.1%)
Number of subjects: 153
Study 11023140 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (goal HbA(1c) 9.1%)
Number of subjects: 153
Study 9083166 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (124 +/- 22 mg per day)
Number of subjects: 44
Study 9083166 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release hydromorphone (30 +/- 6 mg per day)
Number of subjects: 44
Study 7689826 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation of extrafoveal CNV
Number of subjects: 228
Study 7689826 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral neovascular maculopathy
Number of subjects: 228
Study 7689826 — intervention group
Group type: COMPARATOR
Intervention: Unilateral neovascular maculopathy
Number of subjects: 228
Study 3789915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose doxorubicin therapy
Number of subjects: 118
Study 3789915 — intervention group
Group type: COMPARATOR
Intervention: Low-dose doxorubicin therapy
Number of subjects: 118
Study 30075780 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive power toothbrush (IPT) - Oral-B® ProfessionalCare 6000 with Bluetooth
Number of subjects: 60
Study 30075780 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MT) - Oral-B® Indicator soft manual toothbrush
Number of subjects: 60
Study 27385662 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled BP (HT2 group)
Number of subjects: 276
Study 27385662 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled BP (HT1 group)
Number of subjects: 276
Study 27385662 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 276
Study 24780850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiskal methylene blue injection
Number of subjects: 16
Study 23333134 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week slackline training
Number of subjects: 24
Study 23333134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no slackline training)
Number of subjects: 24
Study 20192136 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration anesthesia
Number of subjects: 85
Study 20192136 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 85
Study 18334911 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 12 mg/d
Number of subjects: 1943
Study 18334911 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 4-8 mg/d
Number of subjects: 1943
Study 18334911 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 10-16 mg/d
Number of subjects: 1943
Study 18334911 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 20-24 mg/d
Number of subjects: 1943
Study 18334911 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 15 mg/d
Number of subjects: 1943
Study 18334911 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4-8 mg/d
Number of subjects: 1943
Study 18334911 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 1943
Study 16337518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (45 mg)
Number of subjects: 14
Study 16337518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 14602790 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (0.04, 0.06, and 0.08 microg.kg(‐1).min(‐1))
Number of subjects: 16
Study 14602790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 16
Study 10759336 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort extract (hypericum Ze 117)
Number of subjects: 240
Study 10759336 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 240
Study 8723448 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G (3 g every 6 hours)
Number of subjects: 46
Study 8723448 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg every 24 hours)
Number of subjects: 46
Study 1328358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (5-10 mg norethynodrel with mestranol 0.075-0.15 mg or conjugated estrogens 0.625 mg)
Number of subjects: 64
Study 1328358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal therapy)
Number of subjects: 64
Study 1328358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 64
Study 3526804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 1,600 mg i.v. preoperatively
Number of subjects: 100
Study 3526804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30029756 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership intervention (experimental group)
Number of subjects: 0
Study 30029756 — intervention group
Group type: COMPARATOR
Intervention: Routine home visits (control group)
Number of subjects: 0
Study 26983925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cream applied from wrist to shoulder
Number of subjects: 31
Study 26983925 — intervention group
Group type: COMPARATOR
Intervention: Neutral cream (placebo) applied to the same skin area
Number of subjects: 31
Study 26983925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cream
Number of subjects: 31
Study 26983925 — intervention group
Group type: COMPARATOR
Intervention: Neutral cream (placebo)
Number of subjects: 31
Study 24106340 — intervention group
Group type: EXPERIMENTAL
Intervention: Active doxycycline (100 mg BID for 7 days)
Number of subjects: 184
Study 24106340 — intervention group
Group type: COMPARATOR
Intervention: Placebo doxycycline
Number of subjects: 184
Study 24106340 — intervention group
Group type: EXPERIMENTAL
Intervention: Active azithromycin
Number of subjects: 184
Study 24106340 — intervention group
Group type: COMPARATOR
Intervention: Placebo azithromycin
Number of subjects: 184
Study 21880289 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HOPR) defined as OPR ≥235 P2Y12 reactivity units
Number of subjects: 809
Study 21880289 — intervention group
Group type: COMPARATOR
Intervention: Normal on-treatment platelet reactivity (non-HOPR)
Number of subjects: 809
Study 15937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging intervention providing smoking cessation advice, support, and distraction (5 messages per day for 1 month, then 3 per week until 26-week follow-up)
Number of subjects: 1705
Study 15937529 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1705
Study 15937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging intervention
Number of subjects: 1705
Study 11896839 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial denture with plaque control and professional prophylaxis
Number of subjects: 30
Study 11896839 — intervention group
Group type: COMPARATOR
Intervention: Removable partial denture without plaque control and professional prophylaxis
Number of subjects: 30
Study 9707453 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 26
Study 9707453 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 26
Study 8005278 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. administration of 50 g of human albumin diluted in 500 mL of sodium chloride 0.9%
Number of subjects: 31
Study 8005278 — intervention group
Group type: COMPARATOR
Intervention: sodium chloride 0.9% solution
Number of subjects: 31
Study 8005278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 2686741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g twice daily
Number of subjects: 111
Study 2686741 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 500 mg three times a day
Number of subjects: 111
Study 782262 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 39
Study 782262 — intervention group
Group type: COMPARATOR
Intervention: Trihexyphenidyl
Number of subjects: 39
Study 12454840 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.1 mg/day
Number of subjects: 169
Study 12454840 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 169
Study 12454840 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 169
Study 12454840 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.1 mg/day and 0.5 mg/day
Number of subjects: 169
Study 31960071 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate continuous training combined with resistance training (RT)
Number of subjects: 63
Study 31960071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training with RT
Number of subjects: 63
Study 31960071 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 63
Study 31960071 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF responders (exercise group with improved CRF)
Number of subjects: 63
Study 31960071 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF non-responders (exercise group without improved CRF)
Number of subjects: 63
Study 29891215 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ECT (N=15)
Number of subjects: 27
Study 29891215 — intervention group
Group type: COMPARATOR
Intervention: Sham (N=12)
Number of subjects: 27
Study 27659102 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral to inpatient treatment (contract for self-referral, maximum 5 days, quarantine time of 14 days between stays)
Number of subjects: 53
Study 27659102 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 53
Study 24797321 — intervention group
Group type: EXPERIMENTAL
Intervention: ADH1B*2/*2 group with 0.25 g/kg EtOH
Number of subjects: 24
Study 24797321 — intervention group
Group type: EXPERIMENTAL
Intervention: ADH1B*2/*2 group with 0.5 g/kg EtOH
Number of subjects: 24
Study 24797321 — intervention group
Group type: EXPERIMENTAL
Intervention: ADH1B*2/*2 group at all dosages of EtOH
Number of subjects: 24
Study 24797321 — intervention group
Group type: COMPARATOR
Intervention: ADH1B*1/*2 group at 0.5 g/kg EtOH
Number of subjects: 24
Study 22928903 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dental treatment for severe dental caries
Number of subjects: 86
Study 22928903 — intervention group
Group type: COMPARATOR
Intervention: Control (regular dental treatment)
Number of subjects: 86
Study 20361072 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM‐III symbiotic mixture, 10 ml three times a day
Number of subjects: 46
Study 20361072 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM‐III symbiotic mixture
Number of subjects: 46
Study 18519826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 550
Study 18519826 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride
Number of subjects: 550
Study 18519826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 15643674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (10-contact, 18-week duration)
Number of subjects: 237
Study 15643674 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 237
Study 12042548 — intervention group
Group type: EXPERIMENTAL
Intervention: ELA-Max (4% liposomal lidocaine)
Number of subjects: 120
Study 12042548 — intervention group
Group type: COMPARATOR
Intervention: EMLA (eutectic mixture of local anesthetics)
Number of subjects: 120
Study 10210074 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT)
Number of subjects: 106
Study 10210074 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus (ST)
Number of subjects: 106
Study 10210074 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus and gracilis (ST/G)
Number of subjects: 106
Study 7610222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 72
Study 7610222 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support therapy
Number of subjects: 72
Study 7610222 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 72
Study 2379533 — intervention group
Group type: EXPERIMENTAL
Intervention: Furegrelate 800 mg
Number of subjects: 24
Study 2379533 — intervention group
Group type: EXPERIMENTAL
Intervention: Furegrelate 1600 mg
Number of subjects: 24
Study 2379533 — intervention group
Group type: EXPERIMENTAL
Intervention: Furegrelate (all doses)
Number of subjects: 24
Study 2379533 — intervention group
Group type: EXPERIMENTAL
Intervention: Furegrelate (higher doses)
Number of subjects: 24
Study 2379533 — intervention group
Group type: EXPERIMENTAL
Intervention: Furegrelate
Number of subjects: 24
Study 2379533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 319355 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 174
Study 319355 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 174
Study 31321514 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal DNA methylations and gene expressions for MS
Number of subjects: 0
Study 31321514 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal genes enriched in KEGG pathways and GO terms
Number of subjects: 0
Study 31321514 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-associated SNPs in DDR1
Number of subjects: 0
Study 31321514 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma MICB and Granzyme A levels
Number of subjects: 0
Study 31321514 — intervention group
Group type: EXPERIMENTAL
Intervention: m6A-SNPs rs923829 and METTL21B expression level
Number of subjects: 0
Study 28647451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness, cognitive based therapy
Number of subjects: 179
Study 26195978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Interventions (CI)
Number of subjects: 127
Study 26195978 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activities (PA)
Number of subjects: 127
Study 26195978 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Reminiscence Approach (GRA)
Number of subjects: 127
Study 23513242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfibrotic ILA
Number of subjects: 884
Study 23513242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrotic ILA
Number of subjects: 884
Study 23513242 — intervention group
Group type: COMPARATOR
Intervention: Overall prevalence of ILA
Number of subjects: 884
Study 23513242 — intervention group
Group type: COMPARATOR
Intervention: Equivocal for ILA
Number of subjects: 884
Study 23513242 — intervention group
Group type: COMPARATOR
Intervention: Fibrotic ILA pattern
Number of subjects: 884
Study 23513242 — intervention group
Group type: COMPARATOR
Intervention: Nonfibrotic ILA pattern
Number of subjects: 884
Study 23513242 — intervention group
Group type: COMPARATOR
Intervention: Mixed fibrotic and nonfibrotic ILA pattern
Number of subjects: 884
Study 21528593 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints selected according to syndrome differentiation (Fengchi (GB 20), Quchi (LI 11), Zusanli (ST 36), Sanyinjiao (SP 6) plus supplementary points according to syndrome differentiation)
Number of subjects: 135
Study 21528593 — intervention group
Group type: COMPARATOR
Intervention: Control group received acupuncture at main points only (Fengchi (GB 20), Quchi (LI 11), Zusanli (ST 36), Sanyinjiao (SP 6))
Number of subjects: 135
Study 19447837 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.006 microg/kg/min IV BNP for 72 h
Number of subjects: 24
Study 19447837 — intervention group
Group type: COMPARATOR
Intervention: 0.003 microg/kg/min IV BNP for 72 h
Number of subjects: 24
Study 16456433 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI), average duration 30 minutes, performed by social worker or trauma surgeon
Number of subjects: 126
Study 16456433 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 126
Study 16456433 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 126
Study 16456433 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior number of DUIs
Number of subjects: 126
Study 16456433 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 126
Study 16456433 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol screening score
Number of subjects: 126
Study 14722028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp at 15 mM (trial B)
Number of subjects: 10
Study 14722028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp (trial C)
Number of subjects: 10
Study 14722028 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia (trial A, control)
Number of subjects: 10
Study 14722028 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials (A, B, C)
Number of subjects: 10
Study 12164031 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral iron supplementation (100 mg elemental iron)
Number of subjects: 92
Study 12164031 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly oral iron supplementation (100 mg elemental iron)
Number of subjects: 92